Flu vaccine effectivness 2023/2024

Whitaker, Findlay et al.

Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom

Influenza and Other Respiratory Viruses

Wiley Online Library

First published: 21 May 2024

DOI: https://doi.org/10.1111/irv.13284

This study found evidence of moderate flu vaccine effectiveness in both children and adults. Their results concur with those reported for Canada during the early 2023/2024 season, who also reported moderate vaccine effectiveness.

During the 2022/2023 season results were lower than those reported for the 2023/2024 season, especially among those aged 65 and above.

The distribution of influenza vaccine types among controls. Those aged 2–17 primarily received live attenuated influenza vaccine (LAIV) via nasal spray, those aged 18–64 mostly received quadrivalent cell-based vaccine (QIVc) and those aged ≥ 65 mostly received adjuvanted egg-based vaccine (aQIV). Use of other vaccine types—standard-dose quadrivalent egg-based vaccines (QIVe) and recombinant quadrivalent vaccines (QIVr)—was limited.